USFDA updates Camzyos label to reduce echocardiography monitoring requirements, contraindications: Bristol Myers Squibb Ruchika Sharma18 April 2025 11:00 AM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for...
Mavacamten Misses Primary Endpoints in Phase 3 Trial for Non-Obstructive HCM Dr. Kamal Kant Kohli17 April 2025 8:00 AM ISTBristol Myers Squibb announced that mavacamten did not achieve statistical significance in meeting the dual primary endpoints in the Phase 3...
Bristol Myers Squibb heart disease drug fails to meet main goals in late-stage study Ruchika Sharma16 April 2025 9:30 AM ISTPrinceton: Bristol Myers Squibb has announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult...
Mavacamten may Improve Cardiac Biomarkers in HFpEF Patients, Early trial Results Show Promise Dr. Prem Aggarwal8 Oct 2024 9:00 AM ISTUSA: A recent study from the EMBARK-HFpEF trial has revealed promising results regarding using mavacamten, a cardiac myosin inhibitor, in patients...
Approval of Waiver on Government Site Condition for Bristol Myers Cardiac Drug Mavacamten Trial: CDSCO Panel Dr. Divya Colin10 Sept 2024 6:00 PM ISTNew Delhi: Reviewing the proposal presented by Bristol-Myers, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
CDSCO Panel Grants Bristol-Myers Squibb's Protocol Amendment proposal for Mavacamten Dr. Divya Colin7 Feb 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved the drug major...
Mavacamten new hope for patients with symptomatic obstructive hypertrophic cardiomyopathy Niveditha Subramani1 Sept 2023 10:00 AM ISTHypertrophic cardiomyopathy (HCM) is a myocardial disorder clinically characterized by left ventricular (LV) hypertrophy which is usually inherited....
Bristol Myers Squibb bags European Commission nod for heart disease treatment Camzyos Ruchika Sharma27 Jun 2023 11:31 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved CAMZYOS (mavacamten, 2.5 mg, 5 mg, 10 mg,...
FDA approves mavacamten for hypertrophic cardiomyopathy Jacinthlyn Sylvia19 Jun 2023 9:30 AM ISTBristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to...
Bristol Myers Squibb gets positive CHMP opinion recommending nod for CAMZYOS for treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy Ruchika Sharma30 April 2023 12:15 PM ISTPrinceton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Mavacamten therapy increases functional outcome in OHCM patients: JAMA Jacinthlyn Sylvia23 Jan 2023 10:30 AM ISTMavacamten enhanced a variety of cardiopulmonary exercise testing (CPET) indicators other than peak oxygen uptake (pVO2), showing consistent and wide...
Mavacamten improves health status of patients of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Lancet Dr. Shravani Dali13 July 2021 9:00 AM ISTMavacamten significantly showed better health status as compared to the placebo in patients with symptomatic obstructive hypertrophic...
